Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

BACKGROUND: Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent su...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichhorn, Florian, Klotz, Laura V., Bischoff, Helge, Thomas, Michael, Lasitschka, Felix, Winter, Hauke, Hoffmann, Hans, Eichhorn, Martin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498462/
https://www.ncbi.nlm.nih.gov/pubmed/31046714
http://dx.doi.org/10.1186/s12885-019-5624-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498462/
https://www.ncbi.nlm.nih.gov/pubmed/31046714
http://dx.doi.org/10.1186/s12885-019-5624-2

Ejemplares similares